3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Lymphoid
3
Plasma cell
2
Dermatologic
1
Conditions
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Peripheral Blood Stem Cell Transplantation
41
fludarabine phosphate
33
Cyclophosphamide
31
Mycophenolic Acid
25
Whole-Body Irradiation
22
Cyclosporine
22
Busulfan
21
Tacrolimus
20
Antilymphocyte Serum
17
Methotrexate
16
Filgrastim
14
Etoposide
12
Radiotherapy
11
Psychiatric Rehabilitation
11
Melphalan
11
Methylprednisolone
10
Flow Cytometry
10
Therapeutics
9
Polymerase Chain Reaction
8
Gemcitabine
8
Rituximab
7
sargramostim
6
Vorinostat
6
Sirolimus
6
Cord Blood Stem Cell Transplantation
6
Transplantation
5
Nivolumab
5
Dexamethasone
5
Calcium Dobesilate
5
Bortezomib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
abexinostat
×
Dermatologic
×
Clear all
NCT00724984
2014-04-07
PCYC-0403
Pharmacyclics LLC.
Phase 1/2
Completed
55 enrolled
11 charts